PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

APR 1 3 2004 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwo

Substitute for form TRADPAR

Sheet

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	Unknown				
Filing Date	November 3, 2003				
First Named Inventor	Byrd, et al.				
Art Unit	Unknown				
Examiner Name	Unknown				
Attorney Docket Number	18525/04052				

Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
initials*	No.¹	Number-Kind Code ^{2 (7 known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
W		^{US-} 5447841		Gray, et al.	
1		^{US-} 5491224		Bittner, et al.	
		^{US-} 5756696		Gray, et al.	
		^{US-} 5776688		Bittner, et al.	
W		^{US-} 6277569		Bittner, et al.	
		US-			
		US-			
		US-			
la .		US-			
		US-			
		US-			
		US-			* * * * * * * * * * * * * * * * * * * *
		US-			
		US-			
		US-			
-		US∙			
		US-			
		US-	1		
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
						<u> </u>
	ļ					
	<u> </u>	A 04				
Examiner	1	1 21-11		Date		

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for foot THANK **Application Number** Unknown Filing Date INFORMATION DISCLOSURE November 3, 2003 STATEMENT BY APPLICANT First Named Inventor Byrd, et al. Art Unit Unknown (Use as many sheets as necessary) **Examiner Name** Unknown Attorney Docket Number Sheet 18525/04052 2

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
<i>Y</i>	АА	BYRD, ET AL., "Interphase Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia May Predict Response to Rituximab." Cancer Research 63 (January 1, 2003), pp. 36-38.	
-	АВ	DOHNER, ET AL., "Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia." The New England Journal of Medicine (December 28, 2000) pp. 1910-1916.	
4	AC	CHESON, ET AL., "National Cancer Institute - Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: Revised Guidelines for Diagnosis and Treatment." Blood,	
		Vol. 87, No. 12 (June 15, 1996) pp. 4990-4997.	
	AD	BYRD, ET AL., "Rituximab Using a Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Actiivty and	
		Acceptable Toxicity." Journal of Clinical Oncology, Vol. 19, No. 8 (April 15, 2001) pp. 2153-2164.	
	AE	KAY, ET AL., "Chronic Lymphocytic Leukemia." Hematology (2002) pp. 193-213.	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	AF	HITT, EMMA., "New Directions in Hematologic Malignancies; An Interview with John C. Byrd, MD." Medscape from WbMD, pp.1-2.	
	AG	LOZANSKI, ET AL., "Alemtuzumab is an Effective Therapy for Chronic Lymphocytic Leukemia with P53 Mutations and Deletions." Abstract, Blood (01/15/04).	
J			

Examiner	101/	Date	7 - 1	Ī
Signature	199	Considered	J-8-66	

^{*}EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OIPE 2 AUB 2 1 2005

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute AON A 49/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/700,264				
Filing Date	November 3, 2004				
First Named Inventor	John Byrd				
Art Unit	1645				
Examiner Name	Not yet assigned				
Attorney Docket Number	18525 04052				

			U. S. PATENT D		. 	
Examiner Initials*	No.1		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ^{2 (f known)} US-			Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		<u> </u>		
		US-				
	1	US-				
		US-				
		US-				
		US-				
	 	US-				
	<u> </u>	US-				
		US-		······································		
		US-				
	†	US-		***************************************		
	1	US- ,				
		US-				
	\vdash	US				

Examiner	Cite	Foreign Patent Document	IGN PATENT DOCU Publication	Name of Patentee or	Pages, Columns, Lines,	T
Initials*	No.1	Totalgar atem bocament	Date	Applicant of Cited Document	Where Relevant Passages	l
		Country Code ^{3 "} Number ⁴ "Kind Code ⁵ (d known)	MM-DD-YYYY		Or Relevant Figures Appear	_
						Ļ
					ļ	F
						┢
						┝
					 	₽

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO			o required to respond to a consector	of Information unless it contains a valid OMB control number. Complete if Known
0000		IR	DEMAN	Application Number	10/700,264
INF	ORMATION	DIS	CLOSURE	Filing Date	November 3, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	John Byrd
	(Use as many she	ote se e	acassani	Art Unit	1645
	1036 as many sm	013 03 11	ecessary;	Examiner Name	Not yet assigned
Sheet	2	of	2	Attorney Docket Number	18525.04052

		NON PATENT LITERATURE DOCUMENTS	
Initials* No.1 the item (book, magazine, journal, se		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
M	1	International Search Report for PCT application no. PCT/US03/35225.	
	2	Rai, K.R., Chronic Lymphocytic Leukemia: Case-Based Session Hematology 2001, Vol1, page 140-156.	
	3	Lundin, J. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with	
		B-cell chronic lymphcytic leukemia (B-CLL) BLOOD, 2002 Vol. 100, page 768-773.	
	4	Navarro, B., Association and clonal distribution of trisomy 12 and 13q14 deletions in chronic lymphocytic leukaemia, Br J Haemotol. 1998 Sep;102(5):1330-1334.	i
M	5	Jose A. Interphase Cytogenetics in Chronic Lymphocytic Leukemia, Cancer Genet Cytogenet, 1997, 94:52-58.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.